After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...